In two months preceding the date of filing, officers of Janssen-Ortho have been engaged in lobbying activities related to: a. The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR);b. The on-going work of the Patented Medicine Prices Review Board as it relates to the pricing of Janssen-Ortho molecules and drugs;c. Industry Canada's Regulations Amending the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") and Health Canada's Regulations Amending the Food and Drug Regulations.d. Health Canada's proposal to add drug tramadol to the Controlled Drugs and Substance Act (CDSA) and the Schedule of the Narcote Control Regulations (NCR).
Objets poursuivis : Renseignements prospectifs :
In the next six months, officers of Janssen-Ortho will be engaged in lobbying activities related to: a. The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR);b. The on-going work of the Patented Medicine Prices Review Board as it related to the pricing of Janssen-Ortho molecules and drug. c. Health Canada's proposal to add the drug tramadol to the Controlled Drugs and Substance Act (CDSA) and the Schedule of the Narcotic Control Regulations (NCR).
Détails sur l'objet indiqué
Catégories
Description
Politique ou programme
Any future work of the Commission on the Future of Health Care in Canada.
Règlement
Health Canada's proposal to add the drug tramadol to the Controlled Drugs and Substance Act (CDSA) and the Schedule of the Narcotic Control Regulations (NCR).
Règlement
Health Canada's Regulations Amending the Food and Drug Regulations.
Politique ou programme
The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR) and its study of Post Marketing Surveillance
Règlement
The monitoring of Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
Règlement
The monitoring of Industry Canada's Regulations Amending the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations").
Politique ou programme
The on-going work of the Patented Medicine Prices Review Board as it relates to the pricing of Janssen-Ortho molecules and drugs.